De novo
Biotherapeutics is
a platform biotechnology company developing mRNA encoded,
NK cell-engaging bi- or multi-specific antibodies with a focus on oncology.
We are dedicated to developing next-generation immuno-oncology therapeutics in order to provide solutions for unmet medical needs especially in cancer. Our platform aims to develop bi-, multi-specific antibody via mRNA/lipid nanoparticle technology and to harness this mRNA-encoded antibody to engage patients’ own NK cells to directly target cancer cells.
Founded in September 2021 and based in Seoul, the Republic of Korea, De novo Biotherapeutics has qualified experts and scientists from industry and academia, which is a team of passionate people and is unrelentingly dedicated to bringing innovative therapies to patients in need.